Association of C-reactive Protein-albumin-lymphocyte Index (CALLY) With All-cause Mortality in Di… (NCT06976359) | Clinical Trial Compass
CompletedNot Applicable
Association of C-reactive Protein-albumin-lymphocyte Index (CALLY) With All-cause Mortality in Diabetic Patients
China3,988 participantsStarted 2025-04-08
Plain-language summary
Based on retrospective cohort data from 3,988 diabetic patients in the NHANES database, this study is the first to show a significant negative correlation between the CALLY index and all-cause mortality in diabetic patients, with good predictive ability for their survival risk. Our findings can help clinicians better assess disease progression in diabetic patients and provide a reference for personalized, precision medicine.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
(1) self-reported doctor-diagnosed diabetes; (2) fasting blood glucose ≥ 7.0 mmol/L; (3) two-hour oral glucose tolerance test blood glucose ≥ 11.1 mmol/L; (4) glycated hemoglobin A1c (HbA1c) ≥ 6.5%; or (5) use of hypoglycemic medication.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at something called the CALLY index — a combination of C-reactive protein, albumin, and lymphocyte levels — to predict death risk in people with diabetes; could you check whether my recent lab results include these values, and what they might suggest about my own health?
2Since this was an observational study measuring association rather than testing a treatment, does it change anything about how you currently monitor or manage my diabetes, or is it more of a research finding at this stage?
3The study focused on all-cause mortality in diabetic patients — does my specific type of diabetes or any other conditions I have make this kind of inflammatory marker research more or less relevant to my situation?
4Are there already standard tests or monitoring approaches my care team uses that cover what the CALLY index is measuring, or is this index something that isn't yet part of routine diabetes care?
5Based on studies like this one linking inflammation and nutrition markers to long-term outcomes in diabetes, is there anything I should be doing differently right now — like changes to diet, activity, or follow-up testing — that could address those underlying factors?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.